Abstract 1053P
Background
ICIs used across multiple disease sites including both early and advanced stage cancers. Systemic inflammatory markers including neutrophil to lymphocyte ratios (NLR), platelet to lymphocyte ratios (PLR) and lymphocyte to monocyte ratios (LMR) has been found to be prognostic across different tumor types, but less is known about their prognostic role in patients receiving ICIs. Here we used population-level administrative data to evaluate the potential association between NLR, PLR and LMR and overall survival (OS) among patients receiving ICIs.
Methods
We used administrative data deterministically linked across databases to identify a cohort of patients with solid tumors initiating ICI therapy in Ontario, Canada from June 2012 to October 2018 and obtained information on baseline demographics, clinical covariates, inflammatory markers (NLR, PLR, LMR) at the start of ICI, and overall survival (OS). We applied multivariable Cox proportional hazard models to evaluate the impact of NLR, PLR, and LMR on OS, adjusting for sex, age, cancer center, autoimmune history, recent hospitalization and comorbidity score.
Results
Among 4683 patients, median age was 67, 57% male; 46% had lung cancer, 35% melanoma, 9% renal cancers; 40% received nivolumab, 36% pembrolizumab, 17% ipilimumab. Median OS was 317 days. Using previous cutoffs in the literature, 44% of patients had a high NLR (≥ 5), 58% high PLR (≥ 200), and 60% high LMR (≥ 1.5). Among all patients, those with high NLR (aHR=1.80, 95% CI [1.65-1.97] p
Conclusions
Among cancer patients receiving ICIs, higher NLR and PLR and lower LMR were prognostic of OS across cancer types. Further studies validating their prognostic role in ICI therapy is warranted.
Legal entity responsible for the study
The authors.
Funding
ASCO / Conquer Cancer Foundation - Young Investigator Award.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
937P - Pain, fatigue and depression symptom cluster in head and neck cancer survivors
Presenter: Iakov Bolnykh
Session: Poster session 03
938TiP - Phase II TROPHY-IO-HN study of pembrolizumab ±sacituzumab govitecan in first-line recurrent /metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Amanda Psyrri
Session: Poster session 03
941TiP - A phase I/IIa, open-label, dose-finding trial to evaluate safety, immunogenicity, and anti-tumour activity of VB10.16 in combination with pembrolizumab in patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Saira Khalique
Session: Poster session 03
942TiP - A randomized controlled clinical trial of neoadjuvant immunochemotherapy vs up-front surgery in patients with locally advanced resectable oral squamous cell carcinoma (Tophill trial)
Presenter: Laiping Zhong
Session: Poster session 03
Resources:
Abstract
945TiP - JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)
Presenter: Jean-Pascal Machiels
Session: Poster session 03
1002P - A phase Ia study of the myeloid-derived suppressor cell modulator HF1K16 in refractory and metastatic cancer patients: Preliminary efficacy and safety
Presenter: Ruofan Huang
Session: Poster session 03